At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 458 enrolled
Drug / intervention
Sorafenib (Nexavar, BAY43-9006) +1 moredrug
Likely dose
Sorafenib (Nexavar, BAY43-9006) 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
In Brief
A Phase 3 clinical trial evaluating Sorafenib (Nexavar, BAY43-9006) and Placebo for Carcinoma, Hepatocellular. Completed, enrolled 458 participants across 75 sites in 2 countries.
Detailed Summary
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesJapan, South Korea
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedJun 2007
Primary CompletionJul 2009
Study CompletionNov 2010
TodayJul 2026
First PostedJun 29, 2007
Enrollment StartApr 1, 2006
Primary CompletionJul 1, 2009
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.0 years ago
Interventions
Sorafenib (Nexavar, BAY43-9006)drug
Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
Placebodrug
Placebo: matching placebo